1Keesee SK,Briggman JV,Thill G,et al.Utilization of nuclear matrix proteins for cancer diagnosis.Crit Rev Eukaryot Gene Expr,1996,6:189-214.
2Sanchez-Carbayo M,Herrero E,Megias J,et al.Evaluation of nuclear matrix protein 22 as a tumor marker in the detection of transitional cell carcinoma of the bladder.BJU Int,1999,84:706-713.
5Konety BR,Nguyen TST,Dhir R,et al.Detection of bladder cancer using a novel nuclear matrix protein,BLCA-4.Clin Cancer Res,2000,6:2618-2625.
6Konety BR,Nguyen TST,Brenes G,et al.Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer.J Urol,2000,164:634-639.
7Leyh H,Hall R,Mazeman E,et al.Comparison of the bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.Urology.1997,50(1):49.
8Nilgun M,Levent T,Kaya E.Analytical and clinical evaluation of a new urinary tumor marker.Clin Chem Lab Med,2003,41(8):1069-1074.
9Aitanen MP,Hellstrom P,Marttils T,et al.Effect of intravesical instillations the human complement factor H related protein(BTA stat)test.Eur Urol,2001,40:422-426.
10Mahnert B,Tauber S,Kriegmair M,et al.Measurements of complement factor H-related protein(BTA-TRAK assay)and nuclear matrix protein(NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer.Clin Chem Lab Med,2003,41:104-110.
